Última actualización 12 de septiembre de 2026
Key finding
First-phase insulin secretion significantly increased with semaglutide (ETR [95% CI] 3.02 [2.53, 3.60]; p < 0.0001).
The study evaluated the effects of semaglutide on beta cell function and glycaemic control in type 2 diabetes, finding significant improvements in insulin secretion and glucose levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the effects of semaglutide on beta cell function and glycaemic control in type 2 diabetes, finding significant improvements in insulin secretion and glucose levels.
Improving glycaemic control is crucial for managing type 2 diabetes and preventing complications. The significant enhancements in insulin secretion and reductions in glucose levels observed with semaglutide could lead to better long-term outcomes for patients, making it a valuable treatment option in diabetes management.
The study may have limited generalizability due to specific participant characteristics. Potential biases inherent in a randomized controlled trial design. Short duration of follow-up may not capture long-term effects.
Published in
Publication details and source links for this paper.
Christoph K, Kirsten D, Jacob BJ, Mads BA, Anne F. Semaglutide improves beta cell function and glycaemic control in type 2 diabetes. Diabetologia. 2017;60(8):1390-1399. doi:10.1007/s00125-017-4289-0
First-phase insulin secretion increased significantly with semaglutide (ETR 3.02, p < 0.0001).
Second-phase insulin secretion also increased significantly with semaglutide (ETR 2.10, p < 0.0001).
Fasting glucose levels decreased significantly with semaglutide (p < 0.0001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Subcutaneous Semaglutide and Fasting Plasma Glucose (FPG), Glucagon response (AUC 0-24h), Glucose iAUC (OGTT), and 3 more.
This study contributes evidence to
Primary intervention
Subcutaneous Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
6
Evidence pairs
1134
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Subcutaneous Semaglutide → Fasting Plasma Glucose (FPG)
Subcutaneous Semaglutide → Fasting Plasma Glucose (FPG)
Subcutaneous Semaglutide → Glucagon response (AUC 0-24h)
Subcutaneous Semaglutide → Glucagon response (AUC 0-24h)
Subcutaneous Semaglutide → Glucose iAUC (OGTT)
Subcutaneous Semaglutide → Glucose iAUC (OGTT)
Subcutaneous Semaglutide → Insulin secretion rate (ISR) during GGIT
Subcutaneous Semaglutide → Insulin secretion rate (ISR) during GGIT
Subcutaneous Semaglutide → Postprandial insulin incremental area under the curve (iAUC0–3h)
Subcutaneous Semaglutide → Postprandial insulin incremental area under the curve (iAUC0–3h)
Subcutaneous Semaglutide → Second-phase insulin secretion (AUC 10-120 min)
Subcutaneous Semaglutide → Second-phase insulin secretion (AUC 10-120 min)
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Subcutaneous Semaglutide and Fasting Glucose, Subcutaneous Semaglutide and Glucagon response (AUC 0-24h).
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies measuring Glucagon response (AUC 0-24h)
Measures Glucagon response (AUC 0-24h) as a key outcome.
All studies on Subcutaneous Semaglutide
Contributes to Subcutaneous Semaglutide evidence base.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Subcutaneous Semaglutide appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Subcutaneous Semaglutide appears to improve glucagon response (auc 0-24h).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucagon response (AUC 0-24h)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Subcutaneous Semaglutide appears to improve glucose iauc (OGTT).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glucose iAUC (OGTT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Subcutaneous Semaglutide appears to improve insulin secretion rate (ISR) during ggit.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Insulin secretion rate (ISR) during GGIT
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
